{"id":400505,"date":"2020-12-15T17:19:15","date_gmt":"2020-12-15T22:19:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=400505"},"modified":"2020-12-15T17:19:15","modified_gmt":"2020-12-15T22:19:15","slug":"shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/","title":{"rendered":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd."},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, Dec. 15, 2020<\/span> \/PRNewswire\/ —\u00a0WeissLaw LLP<\/a>\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Anchiano Therapeutics Ltd. (“Anchiano” or the “Company”) (NASDAQ: ANCN) in connection with the Company’s proposed merger with Chemomab Ltd. (“Chemomab”), a privately-held clinical-stage biotech company that develops therapeutics for fibrosis-related diseases. \u00a0Anchiano\u00a0will combine with Chemomab via a reverse-merger to create a public company focused on advancing Chemomab’s lead product, CM-101.\u00a0 Upon closing of the proposed transaction, Anchiano shareholders will only own approximately 10% of the combined company, prior to additional PIPE financing.<\/p>\n

\n

\n
\n \"WeissLaw
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n
\n If you own Anchiano shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:<\/u>
\n <\/b>\n <\/p>\n

\n
\n https:\/\/www.weisslawllp.com\/ancn\/<\/a>
\n <\/b>\n <\/p>\n

\n
\n Or please contact:
<\/u>
\n <\/b>
\n
\n Joshua Rubin, Esq.<\/span>
\n
\n <\/b>WeissLaw LLP
1500 Broadway, 16th<\/sup> Floor
New York<\/span>, NY\u00a0 10036
(212)\u00a0682-3025
<\/b>(888) 593-4771
stockinfo@weisslawllp.com<\/a><\/b><\/p>\n

WeissLaw is investigating whether Anchiano’s board acted in the best interest of Anchiano’s public shareholders in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of Chemomab, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to Anchiano’s public shareholders.\u00a0 <\/p>\n

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.\u00a0 We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.\u00a0 If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com<\/a><\/b><\/p>\n

\n \u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd-301193540.html<\/a><\/p>\n

SOURCE WeissLaw LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, Dec. 15, 2020 \/PRNewswire\/ —\u00a0WeissLaw LLP\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Anchiano Therapeutics Ltd. (“Anchiano” or the “Company”) (NASDAQ: ANCN) in connection with the Company’s proposed merger with Chemomab Ltd. (“Chemomab”), a privately-held clinical-stage biotech company that develops therapeutics for fibrosis-related diseases. \u00a0Anchiano\u00a0will combine with Chemomab via a reverse-merger to create a public company focused on advancing Chemomab’s lead product, CM-101.\u00a0 Upon closing of the proposed transaction, Anchiano shareholders will only own approximately 10% of the combined company, prior to additional PIPE financing. If you own Anchiano shares and wish to discuss this investigation or have any questions concerning this notice or your rights … <\/p>\n

Continue reading “SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd.”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-400505","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Dec. 15, 2020 \/PRNewswire\/ —\u00a0WeissLaw LLP\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Anchiano Therapeutics Ltd. (“Anchiano” or the “Company”) (NASDAQ: ANCN) in connection with the Company’s proposed merger with Chemomab Ltd. (“Chemomab”), a privately-held clinical-stage biotech company that develops therapeutics for fibrosis-related diseases. \u00a0Anchiano\u00a0will combine with Chemomab via a reverse-merger to create a public company focused on advancing Chemomab’s lead product, CM-101.\u00a0 Upon closing of the proposed transaction, Anchiano shareholders will only own approximately 10% of the combined company, prior to additional PIPE financing. If you own Anchiano shares and wish to discuss this investigation or have any questions concerning this notice or your rights … Continue reading "SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd."\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-15T22:19:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd.\",\"datePublished\":\"2020-12-15T22:19:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\\\/\"},\"wordCount\":320,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\\\/\",\"name\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\",\"datePublished\":\"2020-12-15T22:19:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd. - Market Newsdesk","og_description":"PR Newswire NEW YORK, Dec. 15, 2020 \/PRNewswire\/ —\u00a0WeissLaw LLP\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Anchiano Therapeutics Ltd. (“Anchiano” or the “Company”) (NASDAQ: ANCN) in connection with the Company’s proposed merger with Chemomab Ltd. (“Chemomab”), a privately-held clinical-stage biotech company that develops therapeutics for fibrosis-related diseases. \u00a0Anchiano\u00a0will combine with Chemomab via a reverse-merger to create a public company focused on advancing Chemomab’s lead product, CM-101.\u00a0 Upon closing of the proposed transaction, Anchiano shareholders will only own approximately 10% of the combined company, prior to additional PIPE financing. If you own Anchiano shares and wish to discuss this investigation or have any questions concerning this notice or your rights … Continue reading \"SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-15T22:19:15+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd.","datePublished":"2020-12-15T22:19:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/"},"wordCount":320,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/","name":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","datePublished":"2020-12-15T22:19:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-anchiano-therapeutics-ltd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400505","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=400505"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400505\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=400505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=400505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=400505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}